These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26683225)

  • 1. Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.
    Hervas-Stubbs S; Soldevilla MM; Villanueva H; Mancheño U; Bendandi M; Pastor F
    Oncotarget; 2016 Jan; 7(4):4522-30. PubMed ID: 26683225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.
    Gefen T; Castro I; Muharemagic D; Puplampu-Dove Y; Patel S; Gilboa E
    Mol Ther; 2017 Oct; 25(10):2280-2288. PubMed ID: 28800954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers.
    Rong Y; Chen H; Zhou XF; Yin CQ; Wang BC; Peng CW; Liu SP; Wang FB
    Oncotarget; 2016 Feb; 7(7):8282-94. PubMed ID: 26882565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.
    Ngiow SF; von Scheidt B; Akiba H; Yagita H; Teng MW; Smyth MJ
    Cancer Res; 2011 May; 71(10):3540-51. PubMed ID: 21430066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia.
    Soldevilla MM; Villanueva H; Bendandi M; Inoges S; López-Díaz de Cerio A; Pastor F
    Biomaterials; 2015 Oct; 67():274-85. PubMed ID: 26231918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aptamers: A Feasible Technology in Cancer Immunotherapy.
    Soldevilla MM; Villanueva H; Pastor F
    J Immunol Res; 2016; 2016():1083738. PubMed ID: 27413756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis.
    Chen F; Zhou J; Luo F; Mohammed AB; Zhang XL
    Biochem Biophys Res Commun; 2007 Jun; 357(3):743-8. PubMed ID: 17442275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Screening and characterization of DNA aptamers with hTNF-alpha binding and neutralizing activity].
    Guo KT; Yan XR; Huang GJ; Xu CX; Chai YS; Zhang ZQ
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):730-3. PubMed ID: 15971588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aptamers: current challenges and future prospects.
    Rozenblum GT; Lopez VG; Vitullo AD; Radrizzani M
    Expert Opin Drug Discov; 2016; 11(2):127-35. PubMed ID: 26630462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors.
    Zhang D; Zheng Y; Lin Z; Liu X; Li J; Yang H; Tan W
    Angew Chem Int Ed Engl; 2020 Jul; 59(29):12022-12028. PubMed ID: 32246555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamers: new arrows to target dendritic cells.
    Ganji A; Varasteh A; Sankian M
    J Drug Target; 2016; 24(1):1-12. PubMed ID: 25950603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of liver cancer-specific aptamers using whole live cells.
    Shangguan D; Meng L; Cao ZC; Xiao Z; Fang X; Li Y; Cardona D; Witek RP; Liu C; Tan W
    Anal Chem; 2008 Feb; 80(3):721-8. PubMed ID: 18177018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute quantification of cell-bound DNA aptamers during SELEX.
    Avci-Adali M; Wilhelm N; Perle N; Stoll H; Schlensak C; Wendel HP
    Nucleic Acid Ther; 2013 Apr; 23(2):125-30. PubMed ID: 23405949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current approaches in SELEX: An update to aptamer selection technology.
    Darmostuk M; Rimpelova S; Gbelcova H; Ruml T
    Biotechnol Adv; 2015 Nov; 33(6 Pt 2):1141-61. PubMed ID: 25708387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells.
    Soldevilla MM; Villanueva H; Casares N; Lasarte JJ; Bendandi M; Inoges S; López-Díaz de Cerio A; Pastor F
    Oncotarget; 2016 Apr; 7(17):23182-96. PubMed ID: 26992239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hi-Fi SELEX: A High-Fidelity Digital-PCR Based Therapeutic Aptamer Discovery Platform.
    Ouellet E; Foley JH; Conway EM; Haynes C
    Biotechnol Bioeng; 2015 Aug; 112(8):1506-22. PubMed ID: 25727321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy.
    Mahlknecht G; Sela M; Yarden Y
    Methods Mol Biol; 2015; 1317():3-15. PubMed ID: 26072398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes.
    Hamula CL; Peng H; Wang Z; Tyrrell GJ; Li XF; Le XC
    Methods; 2016 Mar; 97():51-7. PubMed ID: 26678795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.